We read with great interest the recent contribution by Ludvigsson, et al1. They reported the increased risk of systemic lupus erythematosus (SLE) in 29,000 patients with biopsy-verified celiac disease (CD) and suggested that the association of CD and SLE could be part of the spectrum of “shared autoimmunity.” We would like to add another pathomechanism of the association between the 2 diseases.

SLE is a complex autoimmune disease characterized by dysregulated interactions between autoreactive T and B lymphocytes and the development of antinuclear antibodies2. The novel cytokine interleukin 21 (IL-21) has been found to have a central role in the differentiation and function of B cells3, raising the possibility that IL-21 may contribute to the pathology of B cell-mediated autoimmune disease. Herber, et al studied the effect of blocking IL-21 on disease in the SLE-prone MRL-Fas (lpr) mouse model4. Mice treated for 10 weeks with IL-21 receptor(R)-Fc fusion protein had reduced proteinuria, fewer IgG glomerular deposits, no glomerular basement membrane thickening, reduced levels of circulating dsDNA autoantibodies, total sera IgG1 and IgG2a, and reduced skin lesions and lymphadenopathy, compared with control mice4.

Fina, et al also demonstrated that IL-21 RNA and protein expression were enhanced in duodenal samples from patients with untreated CD, and blockade of IL-21 activity in biopsies of these patients reduced T-bet and interferon-γ secretion6. Further, a recent study showed that CD risk was increased when serum levels of IL-21 were elevated in both untreated and treated CD, compared to controls7.

Therefore, increased IL-21 in CD may be one of the underlying mechanisms for the positive association with SLE, although Ludvigsson, et al did not measure IL-21 levels. Further studies should be performed to determine whether IL-21 might be related to the development of the 2 diseases at the same time.